O
Oh Suk Kwon
Researcher at Korea Research Institute of Bioscience and Biotechnology
Publications - 11
Citations - 89
Oh Suk Kwon is an academic researcher from Korea Research Institute of Bioscience and Biotechnology. The author has contributed to research in topics: Gene & Fusion gene. The author has an hindex of 6, co-authored 10 publications receiving 77 citations.
Papers
More filters
Journal ArticleDOI
Efficient myogenic differentiation of human adipose-derived stem cells by the transduction of engineered MyoD protein.
TL;DR: The engineered MyoD protein, a key transcription factor for myogenesis, was designed to contain the TAT protein transduction domain for cell penetration and the membrane-disrupting INF7 peptide, which is an improved version of the HA2 peptide derived from influenza.
Journal ArticleDOI
Regulation of the Ubiquinone (Coenzyme Q) Biosynthetic Genes ubiCA in Escherichia coli
TL;DR: The variations in transcription of the operon under different nutritional conditions and in the regulatory mutants, arcA, fnr, and narXL are presented, suggesting that the ubiCA genes are organized into an operon.
Journal ArticleDOI
Characterization of a lichenase isolated from soil metagenome
TL;DR: The recombinant lichenase overexpressed and purified from Escherichia coli was able to efficiently hydrolyze both barley β-glucan and lichenan and showed maximal activity at a pH of 6.0 at 50°C.
Journal ArticleDOI
Molecular cloning of levan fructotransferase gene from Arthrobacter ureafaciens K2032 and its expression in Escherichia coli for the production of difructose dianhydride IV
Chul Ho Kim,E K Jang,Soonchoen Kim,K H Jang,Kang Sang-Hyeon,Ki-Bang Song,Oh Suk Kwon,Sang Ki Rhee +7 more
TL;DR: Aims: To clone and overexpress a novel levan fructotransferase gene lftA from Arthrobacter ureafaciens K2032.
Journal ArticleDOI
Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer
TL;DR: Developing a VLP production and delivery system using B. subtilis will be helpful, in that the vaccine may be convenient production as an antigen delivery system and VLPs thus produced will be safer for human use than those purified from Gram-negative strains such as Escherichia coli.